High Rates of Adherence to Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir and Ribavirin in Patients With Cirrhosis: Data From the Turquoise-II Study

被引：0
|
作者：
Pol, Stanislas
Andreone, Pietro
Lee, Samuel
Bourliere, Marc
Bourgeois, Stefan
Tang, Yuanyuan
Trinh, Roger
Martinez-Tristani, Marisol
Pockros, Paul J.
机构：
来源：
GASTROENTEROLOGY | 2015年 / 148卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Tu1019
引用
收藏
页码：S1086 / S1086
页数：1
相关论文
共 50 条
  • [31] Turquoise-III: 12-Week Ribavirin-Free Regimen Of Ombitasvir/Paritaprevir/R And Dasabuvir For Patients With HCV Genotype 1B And Cirrhosis
    Poordad, Fred
    Feld, Jordan J.
    Trinh, Roger
    Horsmans, Yves J.
    Elkhashab, Magdy
    Bourgeois, Stefan
    Lee, Samuel S.
    Moreno, Christophe
    Bernstein, David
    Younes, Ziad
    Polepally, Akshanth R.
    Howieson, Kevin
    Fu, Bo
    Ball, Greg
    Shulman, Nancy
    Tam, Edward
    HEPATOLOGY, 2015, 62 : 724A - 724A
  • [32] Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America
    Mendizabal, Manuel
    Haddad, Leila
    Gallardo, Patricia E.
    Ferrada, Alejandro
    Soza, Alejandro A.
    Adrover, Raul
    Aravena, Edmundo
    Roblero, Juan P.
    Prieto, Jhon
    Vujacich, Claudia
    Romero, Gustavo
    Munoz, Alberto
    Anders, Margarita
    Hernandez, Nelia
    Coccozella, Daniel
    Gruz, Fernando
    Reggiardo, Maria V.
    Ruf, Andres E.
    Varon, Adriana
    Cartier, Mariano
    Perez Ravier, Roberto
    Ridruejo, Ezequiel
    Peralta, Mirta
    Poncino, Daniel
    Vorobioff, Julio
    Aballay Soteras, Gabriel
    Silva, Marcelo O.
    JOURNAL OF MEDICAL VIROLOGY, 2017, 89 (09) : 1590 - 1596
  • [33] Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older
    Trifan, Anca
    Stanciu, Carol
    Gheorghe, Liana
    Iacob, Speranta
    Curescu, Manuela
    Prelipcean, Cristina Cijevschi
    Stefanescu, Gabriela
    Girleanu, Irina
    Chiriac, Stefan
    Mihai, Catalina
    Brisc, Ciprian
    Goldis, Adrian
    Sporea, Ioan
    Miftode, Egidia
    Bataga, Simona
    Rogoveanu, Ion
    Preda, Carmen
    Caruntu, Florin Alexandru
    Singeap, Ana-Maria
    MEDICINE, 2017, 96 (50)
  • [34] Fibrosis Progression and Incidence of Cirrhosis and Hepatic Decompensation in Persons Treated with Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir: Results from ERCHIVES
    Simon, Tracey G.
    Yan, Peng
    Kort, Jens
    Butt, Adeel A.
    HEPATOLOGY, 2017, 66 : 602A - 602A
  • [35] Outcome of patients with compensated liver cirrhosis with hepatitis B virus plus hepatitis C virus coinfection treated with paritaprevir/ombitasvir/ritonavir, dasabuvir with ribavirin: a national cohort study
    Preda, C.
    Popescu, C.
    Constantinescu, I.
    Manuc, M.
    Tugui, L.
    Voiosu, R.
    Ceausu, E.
    Diculescu, M.
    Oproiu, A.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S295 - S296
  • [36] The Efficacy of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir with or without Ribavirin in Patients with Hepatitis C Undergoing Chronic Haemodialysis: A Single Center Experience
    Danis, Nilay
    Pullukcu, Husnu
    Yamazhan, Tansu
    Ersoz, Galip
    Unal, Nalan
    Gunsar, Fulya
    Turan, Ilker
    Karasu, Zeki
    Akarca, Ulus Salih
    VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, 2019, 25 (03): : 109 - 112
  • [37] A Retrospective Cohort Study: Safety and Effectiveness of Elbasvir/Grazoprevir ± Ribavirin Compared With Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir ± Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Infection
    Hung, Hsuan-Yu
    Chen, Chung-Yu
    Liao, Yi-Hsiang
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [38] Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin (RBV) in hepatitis C virus genotype 1-infected patients with compensated cirrhosis and multiple comorbidities
    Popa, R. C.
    Mihai, C.
    Trifan, A.
    Stanciu, C.
    Gheorghe, L.
    Iacob, S.
    Arama, V.
    Rogoveanu, I.
    Diculescu, M.
    Goldis, A.
    Bataga, S.
    Seicean, A.
    Sandulescu, L.
    Nastase, R.
    Molagic, V.
    Brisc, C.
    Curescu, M.
    Prelipcean, C. C.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S732 - S732
  • [39] Changes in markers of liver function in hepatitis C virus genotype 1b Asian patients with compensated cirrhosis treated with ombitasvir/paritaprevir/ritonavir plus dasabuvir with ribavirin in the ONYX-II study
    Heo, J.
    Luo, Y.
    Chuang, W. -L.
    Jia, J.
    Han, K. -H.
    Yu, M. -L.
    Tang, H.
    Lim, Y. -S.
    Peng, C. -Y.
    Xu, M.
    Wang, M.
    Fu, B.
    Mobashery, N.
    Wei, L.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S517 - S518
  • [40] Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis
    Poordad, Fred
    Sedghi, Shahriar
    Pockros, Paul J.
    Ravendhran, Natarajan
    Reindollar, Robert
    Lucey, Michael R.
    Epstein, Michael
    Bank, Leslie
    Bernstein, David
    Trinh, Roger
    Krishnan, Preethi
    Polepally, Akshanth R.
    Unnebrink, Kristina
    Martinez, Marisol
    Nelson, David R.
    JOURNAL OF VIRAL HEPATITIS, 2019, 26 (08) : 1027 - 1030
12345